2 results
Approved WMORecruitment stopped
Primary Efficacy Objective: To define the minimum effective dose (MED) of the oral dose of E4 by evaluating changes in frequency and in severity of moderate to severe vasomotor symptoms (VMS) within each treatment arm at week 4 and 12. Secondary…
Approved WMORecruiting
To evaluate RRS after childbearing with delayed RRO as an alternative for RRSO in BRCA1/2 gene germline mutation carriers. We hypothesize that delay of menopause leads to an improvement of quality of life and sexual functioning, and a decrease in…